

5F
#6
1/10/00

1642

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Thomas E. Northrup
Thomas E. Northrup, Reg. No. 33,268

6-23-2000
Date

Applicant : Sherman)
Serial No. : 09/277,074) Group: 1642
Filed : March 26, 1999)
For : IN VIVO ACTIVATION OF TUMOR-SPECIFIC CYTOTOXIC T CELLS) Examiner: M. Davis
Ref. 04/10/2002 GBUCHETT 001299100
DAN.120062) JUN 10 2002
TECH CENTER 1600/2900) 0240.00 CR
JUN 26 2000
OIPC JC62
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In recognition of its continuing duty to disclose pursuant to 37 CFR §1.56, Applicant hereby submits the present Information Disclosure Statement in compliance therewith.

Pursuant to 37 CFR § 1.98(d), enclosed herewith are copies of the Information Disclosure Statement and Supplemental Information Disclosure Statement and accompanying PTO Forms 1449 filed in parent application 08/355,558 filed on December 14, 1994, now abandoned. Also, pursuant to 37 CFR §1.98(d), copies of the above references are not submitted herewith, as they are available in the parent patent application 08/355,558.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed

06/28/2000 NPIRASASD 00000068 09277074

-01-FC-126

240.00 OP

-1-

Adjustment date: 04/10/2002 GBUCHETT
06/28/2000 NPIRASASD 00000068 09277074
-240.00 OP

Serial No.: 09/277,074

TSRI 433.1 D4



references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR 1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR 1.97 (c), and therefore is accompanied by a check in the amount of \$240.00 as payment of the fee set forth in 37 CFR §1.17 (p).

Also, in accordance with 37 CFR 1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR 1.56 exists.

Respectfully submitted,

Dated: 6-23-2000

By Thomas E. Northrup

Thomas E. Northrup, Reg. No. 33,268

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937